BibTex RIS Cite

Kanser Kök Hücresi ve Notch Yolağında Umut Veren Ortak Embriyonik Dönem İnhibisyonu

Year 2009, Volume: 40 Issue: 1, 23 - 27, 20.07.2014

Gülperi Öktem Serap Uslu Ayşegül Uysal Ayhan Bilir Şule Ayla Burak Soner Çağ Çal

Keywords

Kanser kök hücre notch yolağı verapamil

References

  • 1. Strizzi L, Postovit LM, Margaryan NV, et al. Emerging roles of nodal and Cripto-1: from embryogenesis to breast cancer progression. Breast Dis 2008; 29: 91- 103.
  • 2. Leong KG, Gao WQ. The Notch pathway in prostate development and cancer. Differentiation 2008; 76: 699-716.
  • 3. Raaijmakers MH, Scadden DT. Divided within: heterogeneity within adult stem cell pools. Cell 2008; 135: 1006-1008.
  • 4. Dick JE. Stem cell concepts renew cancer research. Blood 2008; 112: 4793-4807.
  • 5. Pearce DJ, Ridler CM, Simpson C, Bonnet D. Multiparameter analysis of murine bone marrow side population cells. Blood 2004; 103: 2541-2546.
  • 6. Hirschmann-Jax C, Foster AE, Wulf GG, et al. A distinct "side population" of cells in human tumor cells: implications for tumor biology and therapy. Cell Cycle 2005; 4: 203-205.
  • 7. Hirschmann-Jax C, Foster AE, Wulf GG, et al. A distinct "side population" of cells with high drug efflux capacity in human tumor cells. Proc Natl Acad Sci USA 2004; 101: 14228-14233.
  • 8. Patrawala L, Calhoun T, Schneider-Broussard R, et al. Side population is enriched in tumorigenic, stem-like cancer cells, whereas ABCG2+ and ABCG2- cancer cells are similarly tumorigenic. Cancer Res 2005; 65: 6207-6219. 9. Chen J, Crabbe A, Duppen VV, Vankelecom H The notch signaling system is present in the postnatal pituitary: marked expression and regulatory activity in the newly discovered side population. Mol Endocrinol 2006; 20: 3293-3307.
  • 10. Bozkurt KM. Kemoterapi ve Kanser Kök Hücreleri. ‹stanbul: Uyum Yay›nc›l›k; 2007.
  • 11. Marotta LL, Polyak K. Cancer stem cells: a model in the making. Curr Opin Genet Dev 2009; 19: 44-50.
  • 12. Morrow M, Wait RB, Rosenthal RA, Gamelli RL. Verapamil enhances antitunor activity without increasing myeloid toxicity. Surgery 1987; 101: 63-68.
  • 13. fienel F. Klonlamada yeni ufuklar: Kök hücreler. TÜB‹TAK Bilim ve Teknik Dergisi 2002; (410): 44.
  • 14. Cheng XY, O’Neill HC. Oncogenesis and cancer stem cells: Current opinions and future directions. J Cell Mol Med 2009; 16.
  • 15. Ward RJ, Dirks PB. Cancer stem cells: at the headwaters of tumor development. Annu Rev Pathol 2007; 2: 175-189.
  • 16. Szakács G, Jakab K, Antal F, Sarkadi B. Diagnostics of multidrug resistance in cancer. Pathol Oncol Res 1998; 4: 251-257.
  • 17. Licht T, Fiebig HH, Bross KJ, Herrmann F, Berger DP, Shoemaker R, Mertelsmann R. Induction of multipledrug resistance during anti- neoplastic chemotherapy in vitro. Int J Cancer 1991; 49: 630-637
  • 18. BJ, Osborne BA, Miele L. Notch signaling as a therapeutic target in cancer: a new approach to the development of cell fate modifying agents. Oncogene 2003; 22: 6598-6608.
  • 19. Singh SR, Hou SX. Multipotent stem cells in the Malpighian tubules of adult Drosophila melanogaster. J Exp Biol 2009; 212: 413-23.
  • 20. Koch U, Radtke F. Notch and cancer: a double- edged sword. Cell Mol Life Sci 2007; 64: 2746-2762.
  • 21. Bolós V, Blanco M, Medina V, Aparicio G, Díaz-Prado S, Grande E. Notch signalling in cancer stem cells. Clin Transl Oncol 2009; 11: 11-9.
  • 22. Akbulut H, Akbulut KG. Karsinogenez In: Içli F, ed. T›bbi Onkoloji. Ankara: ANTIP Afi T›p Kitaplar› ve Bilimsel Yay›nlar; 1997. p. 23-38.
  • 23. Lecture GFF. Molecular mechanisms of lung cancer. Interaction of environmental and genetic factors. Chest 1996; 109: 14-19.

Year 2009, Volume: 40 Issue: 1, 23 - 27, 20.07.2014

Gülperi Öktem Serap Uslu Ayşegül Uysal Ayhan Bilir Şule Ayla Burak Soner Çağ Çal

References

  • 1. Strizzi L, Postovit LM, Margaryan NV, et al. Emerging roles of nodal and Cripto-1: from embryogenesis to breast cancer progression. Breast Dis 2008; 29: 91- 103.
  • 2. Leong KG, Gao WQ. The Notch pathway in prostate development and cancer. Differentiation 2008; 76: 699-716.
  • 3. Raaijmakers MH, Scadden DT. Divided within: heterogeneity within adult stem cell pools. Cell 2008; 135: 1006-1008.
  • 4. Dick JE. Stem cell concepts renew cancer research. Blood 2008; 112: 4793-4807.
  • 5. Pearce DJ, Ridler CM, Simpson C, Bonnet D. Multiparameter analysis of murine bone marrow side population cells. Blood 2004; 103: 2541-2546.
  • 6. Hirschmann-Jax C, Foster AE, Wulf GG, et al. A distinct "side population" of cells in human tumor cells: implications for tumor biology and therapy. Cell Cycle 2005; 4: 203-205.
  • 7. Hirschmann-Jax C, Foster AE, Wulf GG, et al. A distinct "side population" of cells with high drug efflux capacity in human tumor cells. Proc Natl Acad Sci USA 2004; 101: 14228-14233.
  • 8. Patrawala L, Calhoun T, Schneider-Broussard R, et al. Side population is enriched in tumorigenic, stem-like cancer cells, whereas ABCG2+ and ABCG2- cancer cells are similarly tumorigenic. Cancer Res 2005; 65: 6207-6219. 9. Chen J, Crabbe A, Duppen VV, Vankelecom H The notch signaling system is present in the postnatal pituitary: marked expression and regulatory activity in the newly discovered side population. Mol Endocrinol 2006; 20: 3293-3307.
  • 10. Bozkurt KM. Kemoterapi ve Kanser Kök Hücreleri. ‹stanbul: Uyum Yay›nc›l›k; 2007.
  • 11. Marotta LL, Polyak K. Cancer stem cells: a model in the making. Curr Opin Genet Dev 2009; 19: 44-50.
  • 12. Morrow M, Wait RB, Rosenthal RA, Gamelli RL. Verapamil enhances antitunor activity without increasing myeloid toxicity. Surgery 1987; 101: 63-68.
  • 13. fienel F. Klonlamada yeni ufuklar: Kök hücreler. TÜB‹TAK Bilim ve Teknik Dergisi 2002; (410): 44.
  • 14. Cheng XY, O’Neill HC. Oncogenesis and cancer stem cells: Current opinions and future directions. J Cell Mol Med 2009; 16.
  • 15. Ward RJ, Dirks PB. Cancer stem cells: at the headwaters of tumor development. Annu Rev Pathol 2007; 2: 175-189.
  • 16. Szakács G, Jakab K, Antal F, Sarkadi B. Diagnostics of multidrug resistance in cancer. Pathol Oncol Res 1998; 4: 251-257.
  • 17. Licht T, Fiebig HH, Bross KJ, Herrmann F, Berger DP, Shoemaker R, Mertelsmann R. Induction of multipledrug resistance during anti- neoplastic chemotherapy in vitro. Int J Cancer 1991; 49: 630-637
  • 18. BJ, Osborne BA, Miele L. Notch signaling as a therapeutic target in cancer: a new approach to the development of cell fate modifying agents. Oncogene 2003; 22: 6598-6608.
  • 19. Singh SR, Hou SX. Multipotent stem cells in the Malpighian tubules of adult Drosophila melanogaster. J Exp Biol 2009; 212: 413-23.
  • 20. Koch U, Radtke F. Notch and cancer: a double- edged sword. Cell Mol Life Sci 2007; 64: 2746-2762.
  • 21. Bolós V, Blanco M, Medina V, Aparicio G, Díaz-Prado S, Grande E. Notch signalling in cancer stem cells. Clin Transl Oncol 2009; 11: 11-9.
  • 22. Akbulut H, Akbulut KG. Karsinogenez In: Içli F, ed. T›bbi Onkoloji. Ankara: ANTIP Afi T›p Kitaplar› ve Bilimsel Yay›nlar; 1997. p. 23-38.
  • 23. Lecture GFF. Molecular mechanisms of lung cancer. Interaction of environmental and genetic factors. Chest 1996; 109: 14-19.
There are 22 citations in total.

Details

Primary Language Turkish
Journal Section Araştırmalar
Authors

Gülperi Öktem This is me

Serap Uslu This is me

Ayşegül Uysal This is me

Ayhan Bilir This is me

Şule Ayla This is me

Burak Soner This is me

Çağ Çal This is me

Publication Date July 20, 2014
Published in Issue Year 2009 Volume: 40 Issue: 1

Cite

APA Öktem, G., Uslu, S., Uysal, A., Bilir, A., et al. (2014). Kanser Kök Hücresi ve Notch Yolağında Umut Veren Ortak Embriyonik Dönem İnhibisyonu. Cerrahpaşa Tıp Dergisi, 40(1), 23-27.
AMA Öktem G, Uslu S, Uysal A, Bilir A, Ayla Ş, Soner B, Çal Ç. Kanser Kök Hücresi ve Notch Yolağında Umut Veren Ortak Embriyonik Dönem İnhibisyonu. Cerrahpaşa Tıp Dergisi. July 2014;40(1):23-27.
Chicago Öktem, Gülperi, Serap Uslu, Ayşegül Uysal, Ayhan Bilir, Şule Ayla, Burak Soner, and Çağ Çal. “Kanser Kök Hücresi Ve Notch Yolağında Umut Veren Ortak Embriyonik Dönem İnhibisyonu”. Cerrahpaşa Tıp Dergisi 40, no. 1 (July 2014): 23-27.
EndNote Öktem G, Uslu S, Uysal A, Bilir A, Ayla Ş, Soner B, Çal Ç (July 1, 2014) Kanser Kök Hücresi ve Notch Yolağında Umut Veren Ortak Embriyonik Dönem İnhibisyonu. Cerrahpaşa Tıp Dergisi 40 1 23–27.
IEEE G. Öktem, S. Uslu, A. Uysal, A. Bilir, Ş. Ayla, B. Soner, and Ç. Çal, “Kanser Kök Hücresi ve Notch Yolağında Umut Veren Ortak Embriyonik Dönem İnhibisyonu”, Cerrahpaşa Tıp Dergisi, vol. 40, no. 1, pp. 23–27, 2014.
ISNAD Öktem, Gülperi et al. “Kanser Kök Hücresi Ve Notch Yolağında Umut Veren Ortak Embriyonik Dönem İnhibisyonu”. Cerrahpaşa Tıp Dergisi 40/1 (July 2014), 23-27.
JAMA Öktem G, Uslu S, Uysal A, Bilir A, Ayla Ş, Soner B, Çal Ç. Kanser Kök Hücresi ve Notch Yolağında Umut Veren Ortak Embriyonik Dönem İnhibisyonu. Cerrahpaşa Tıp Dergisi. 2014;40:23–27.
MLA Öktem, Gülperi et al. “Kanser Kök Hücresi Ve Notch Yolağında Umut Veren Ortak Embriyonik Dönem İnhibisyonu”. Cerrahpaşa Tıp Dergisi, vol. 40, no. 1, 2014, pp. 23-27.
Vancouver Öktem G, Uslu S, Uysal A, Bilir A, Ayla Ş, Soner B, Çal Ç. Kanser Kök Hücresi ve Notch Yolağında Umut Veren Ortak Embriyonik Dönem İnhibisyonu. Cerrahpaşa Tıp Dergisi. 2014;40(1):23-7.